The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 25, 2025
Filed:
Oct. 14, 2024
Roaa M. Alreemi, Jeddah, SA;
Hind A. Alkhatabi, Jeddah, SA;
Mohammed A. Baradwan, Jeddah, SA;
Abdelsattar M. Omar, Jeddah, SA;
Moustafa E. El-araby, Cairo, EG;
Yara E. Mansour, Cairo, EG;
Samar S. Fatahala, Cairo, EG;
Ahmed M. Said, Cairo, EG;
Shahenda Mahgoub, Cairo, EG;
Roaa M. Alreemi, Jeddah, SA;
Hind A. Alkhatabi, Jeddah, SA;
Mohammed A. Baradwan, Jeddah, SA;
Abdelsattar M. Omar, Jeddah, SA;
Moustafa E. El-Araby, Cairo, EG;
Yara E. Mansour, Cairo, EG;
Samar S. Fatahala, Cairo, EG;
Ahmed M. Said, Cairo, EG;
Shahenda Mahgoub, Cairo, EG;
University of Jeddah, Jeddah, SA;
King Abdulaziz University, Cairo, EG;
Helwan University, Cairo, EG;
Abstract
Compounds belonging to the group of N-benzyl-2-(4-(4-substituted-1H-1,2,3-triazol-1-yl)phenylacetamides have cytotoxic activities against MCF7 breast cancer cells, and are useful in therapeutic regimes for breast cancer. The N-benzyl-2-(4-(4-substituted-1H-1,2,3-triazol-1-yl)phenylacetamides also have beneficial effects on BAX, BCL-2, MCL-1 and MAPK pathways within MCF& breast cancer cells.